loading page

Serum C1q concentration is associated with disease activity in Chinese Takayasu arteritis patients: a case-control study
  • +4
  • Si Chen,
  • Haixia Luan,
  • Jianxun He,
  • Yan Wang,
  • Xiaoli Zeng,
  • Yongzhe Li,
  • Hui Yuan
Si Chen

Corresponding Author:[email protected]

Author Profile
Haixia Luan
Author Profile
Jianxun He
Author Profile
Xiaoli Zeng
Author Profile
Yongzhe Li
Author Profile


Background: C1q is a crucial component of the classical complement pathway. This study is the first to assess the association between disease activity and serum levels of C1q in Chinese Takayasu arteritis (TA) patients. Methods: Serum C1q levels in 190 TA patients and 154 healthy controls were assessed, and the relationship between serum C1q levels and indices of TA disease activity was analyzed. Moreover, we examined the correlation between serum C1q levels and two traditional inflammatory biomarkers; erythrocyte sedimentation rate (ESR) and hypersensitive CRP (hs-CRP). Results: Serum C1q levels were increased in TA patients compared with healthy controls (p=0.008). TA patients with active disease had higher levels of serum C1q than patients who had inactive disease (p<0.0001). Additionally, treatment-naïve patients had higher serum C1q levels than those who had been treated with corticosteroids or at least one immunosuppressant (p=0.001). Furthermore, a positive correlation between serum C1q levels and traditional inflammatory biomarkers in TA patients was found. The role of C1q in assessing disease activity was studied, and the area under the receiver operating characteristic (ROC) curve (AUC) of C1q for predicting active disease was 0.752,and a serum cutoff value of 167.15 mg/LC1q maximized the ability of disease activity assessment, with a sensitivity/specificity of 77.80%/64.90%. When the three indicators (C1q, ESR and hs-CRP) were combined, the AUC increased to 0.845, and the sensitivity to 84.40%. Conclusions: Serum C1q concentration may be a useful inflammatory marker for TA and a potential factor for evaluating disease activity in TA patients.
Jun 2021Published in Health Science Reports volume 4 issue 2. 10.1002/hsr2.252